Condition: Advanced Melanoma · Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.
This description comes directly from the study's public registry record.
Jun Guo, Prof. Dr. Med · 86-10-88121122 · guoj307@126.com
Always discuss trial participation with your own doctor first.
| Beijing Go Broad Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| The Third People's Hospital of Zhengzhou | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi’an, Shanxi, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07310784